| Titre |
A Phase 1 Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of 225Ac-PSMA-Trillium in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) |
| Protocole ID |
PAnTHA |
| ClinicalTrials.gov ID |
NCT06217822 |
| Type(s) de cancer |
Prostate |
| Phase |
Phase I |
| Stade |
Résistant à la castration - métastatique |
| Type étude |
Clinique |
| Médicament |
225Ac-PSMA-Trillium |
| Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
| Ville |
Montréal |
| Investigateur(trice) principal(e) |
Dr Fred Saad
|
| Coordonnateur(trice) |
Amal Nadiri
514-890-8000 poste 26074
|
| Statut |
 Actif en recrutement |
| Date d'activation |
16-04-2024 |
| Critètes d'éligibilité |
- Female patient with a new histological diagnosis of clinical T1-3 N0 breast cancer (any tumour sub-type).
- Negative lymph node involvement at initial presentation, documented by imaging (US or MRI), fine needle aspiration (FNA) or core needle biopsy.
- Treated with a minimum of 8 weeks NAC, with patients with Her2+ disease receiving targeted anti-Her2+ therapy.
- Marker clip placed in the tumour bed prior to or during neoadjuvant chemotherapy when the tumour can still be identified.
- Treated by BCS with complete excision of the tumour bed and axillary staging surgery (either sentinel lymph node biopsy or axillary lymph node dissection).
- Final pathology demonstrating a pCR [defined as absence of residual invasive and in-situ breast cancer within the breast or lymph nodes (ypT0N0)].
|
| Critètes d'exclusion |
- Age less than 50 years.
- Inflammatory breast cancer or breast cancer invading the skin or chest wall (T4 disease).
- Multicentric disease (i.e., breast cancer involving more than one quadrant in the same breast).
- Prior history of ipsilateral or contralateral in-situ or invasive breast cancer. Patients with a history of lobular carcinoma in-situ (LCIS) are ineligible.
- Synchronous contralateral in-situ or invasive breast cancer.
- BRCA (breast cancer gene) 1 or 2 genetic mutation carrier, or other genetic mutation present associated with increased risk of breast cancer.
- Other previous non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers or other cancers curatively treated with no evidence of disease for ≥ 5 years.
- Inability to complete entire course of neoadjuvant therapy (minimum of 8 weeks of treatment).
- Patients with HR+ (hormone receptor) disease who are not planned to have endocrine therapy initiated.
- Patients with Her2+ disease who have not received or are not planned to receive Her2 targeted therapy.
- ECOG (Eastern Cooperative Oncology Group) performance status > 3.
- Inability to provide informed consent.
|
Groupe d'étude en oncologie du Québec